Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M

Benzinga Newsdesk www.benzinga.com Negative 69.2%

Neg 69.2% Neu 0% Pos 0%

Basic and diluted loss per share remained stable at CHF 0.01 per share for the three-month periods ended March 31, 2026 and 2025.